KSP

THE PHAGE is a medical device company dedicated to advancing health management through the development of artificial intelligence technology. It specializes in analyzing biometric data and daily activities to provide personalized health insights, particularly concerning postprandial blood glucose levels. By leveraging its innovative platform, the company offers AI-driven recommendations that empower individuals to make informed lifestyle changes, ultimately helping them take control of their health and manage their blood glucose levels effectively.

Thermalytica specializes in research, development, and consulting services focused on heat insulating and heat shielding materials. The company provides a range of products, including thermal insulation materials designed to minimize energy loss and environmental impact. Additionally, Thermalytica offers ultra-high temperature thermal barrier coating services essential for hydrogen-fired power generation. By supplying electron beam physical vapor deposition equipment and thermal barrier coating equipment, Thermalytica supports various sectors, including construction materials, industrial plants, and home appliances, by delivering innovative thermal control technologies aimed at addressing critical energy and environmental challenges.

Mira Robotics, Inc. is a Japanese company based in Kawasaki City that specializes in designing and developing a Robot as a Service (RaaS) platform. Established in 2018, the company focuses on providing comprehensive services in robot development, robot intelligence, and cloud collaboration. Mira Robotics aims to integrate software solutions to enhance robotic capabilities across various fields, facilitating advancements in automation and intelligent systems.

Melody International is a manufacturing company that specializes in medical equipment designed for remote medical services. The company has developed an advanced fetal monitoring device that assists healthcare professionals during challenging delivery situations. This device includes a fetal heart monitor, a uterine contraction monitor, and a tablet interface. It features a built-in speaker connected to the transducer via the internet, allowing it to function as a fetal Doppler for monitoring pregnancy. This innovation enables women to assess maternal and fetal health conditions even from distant locations, thereby improving access to essential medical care.

Metcela Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiac diseases. Founded in 2016 and based in Kawasaki, Japan, Metcela specializes in fibroblast-based treatments, particularly its lead asset, MTC001. This therapy utilizes VCAM-1-positive Cardiac Fibroblasts, which are derived from the patient's own heart cells. Rather than replacing damaged cells, the therapy enhances the body's natural healing processes to repair heart tissue and restore a favorable microenvironment. Through its research and development efforts, Metcela aims to offer patients an effective and affordable alternative for treating heart failure.

AdipoSeeds is a biotechnology company focused on addressing the global shortage of platelets by developing an innovative platelet-making system. The company utilizes mesenchymal stem cells to create platelets without the need for complex and costly gene transfer techniques. By pioneering a new blood supply system, AdipoSeeds aims to provide a cost-effective and safe solution for platelet-related treatments. Their technology offers fat-derived platelets that can be utilized in various applications, including blood products and wound care medicine, ultimately contributing to improved healthcare outcomes.

Luxonus is a medical device manufacturing company specializing in photoacoustic technology aimed at early disease detection and diagnosis. The company has developed an advanced imaging device that utilizes optical ultrasonic technology, which combines light and ultrasonic waves to create ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This innovative approach allows for safe and easy imaging without exposure, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and overall health conditions before and after illness.

Ampametry provides neuropsychiatric drugs with AMPA-PET technology. They offers central nervous system drug discovery business AMPA-PET technology.

Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, producing high-performance measurement systems that utilize multi-path scattered field theory. Integral Geometry Science is particularly noted for its microwave mammography system, which addresses challenges in imaging high-density breast tissue. This innovative technology improves the clarity of images, allowing for accurate differentiation between cancerous and normal tissue, thus reducing the need for painful and radiation-exposing conventional screening methods. Additionally, the company manufactures nondestructive inspection systems for lithium-ion batteries, contributing to safety and reliability in battery technology.

iXs is a start-up focused on addressing social challenges through advanced robotic technology. The company specializes in the development of AI-integrated inspection and business robots, which are designed to carry out maintenance inspections across various sectors, including infrastructure, construction, and manufacturing. By engaging in commissioned and joint development projects, iXs aims to enhance the quality of inspections for large-scale infrastructure while alleviating the workload of human operators. In addition to its robotic solutions, iXs offers AI and data service systems that analyze big data to further support clients in addressing their operational issues. The company provides comprehensive support throughout the entire process, from product introduction to ongoing operations, ensuring that its offerings are effectively utilized to meet customer needs.

Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, producing high-performance measurement systems that utilize multi-path scattered field theory. Integral Geometry Science is particularly noted for its microwave mammography system, which addresses challenges in imaging high-density breast tissue. This innovative technology improves the clarity of images, allowing for accurate differentiation between cancerous and normal tissue, thus reducing the need for painful and radiation-exposing conventional screening methods. Additionally, the company manufactures nondestructive inspection systems for lithium-ion batteries, contributing to safety and reliability in battery technology.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

Miraikikai, Inc., established in 2004 and based in Takamatsu, Japan, specializes in the development, manufacturing, distribution, and maintenance of robotics and mechatronics products. The company focuses on creating intelligent mobile robots for professional use, with a particular emphasis on automated solar panel cleaning systems designed for utility-scale plants. These robots utilize artificial intelligence and advanced mechanical design to efficiently remove dust and sand from solar panels without the need for water. Additionally, Miraikikai produces a range of non-contact sensors, such as the 3D Laser Censor, which can be applied to various structures including pipes and tanks. The company also offers technical consultation and development solutions, drawing on extensive research and experience to deliver high-quality, cost-effective robotics solutions.

Metcela Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiac diseases. Founded in 2016 and based in Kawasaki, Japan, Metcela specializes in fibroblast-based treatments, particularly its lead asset, MTC001. This therapy utilizes VCAM-1-positive Cardiac Fibroblasts, which are derived from the patient's own heart cells. Rather than replacing damaged cells, the therapy enhances the body's natural healing processes to repair heart tissue and restore a favorable microenvironment. Through its research and development efforts, Metcela aims to offer patients an effective and affordable alternative for treating heart failure.

Renascience is a research and development firm focused on creating innovative medical solutions to address various health issues. The company engages in the development of pharmaceuticals and medical devices, employing diverse methodologies including artificial intelligence to enhance its offerings. By integrating these advanced technologies, Renascience aims to solve complex medical challenges and improve patient outcomes.

Cyfuse Biomedical K.K. is a biotechnology company based in Tokyo, Japan, that specializes in the research, development, and commercialization of tissue fabrication systems and cell-based products. Founded in 2010, the company offers 3D BioFabrication systems that utilize robotic technology to assemble spheroids into customized 3D shapes, providing innovative solutions for cell delivery in research and therapeutic applications. Cyfuse develops and licenses 3D tissue products for therapeutic use and engages in contract manufacturing for research purposes. The applications of its products include blood vessel grafts for hemodialysis access and coronary artery bypass grafts, cardiac grafts for drug toxicology and myocardial infarction therapy, cartilage grafts for surgical reconstruction, and hepatocyte grafts for drug metabolism studies and hemophilia treatment. Cyfuse Biomedical serves various research and development institutes, including universities, and has established a strategic partnership with Shibuya Kogyo Co., Ltd.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

CODE Meee Inc., founded in 2017 and based in Yokohama, Japan, specializes in the production and marketing of scents. The company offers a comprehensive range of services, including fragrance branding and product planning, tailored to meet the specific needs of individuals and businesses. CODE Meee provides a unique aroma subscription service that delivers personalized scents designed to enhance mental well-being and mood, helping customers reduce stress through carefully curated fragrances. By utilizing data to optimize scent selection, CODE Meee positions itself as a leader in the fragrance industry, focusing on both individual and corporate clients.

Rena Therapeutics Inc. is a pharmaceutical company based in Tsukuba, Japan, founded in January 2015. The company specializes in developing nucleic acid medicines designed for innovative drug delivery systems targeting various tumors, including glioma, melanoma, and several types of leukemia and lymphoma. Rena Therapeutics focuses on addressing unmet medical needs in cancer and other difficult-to-treat diseases by leveraging the advantages of nucleic acid drugs. These advantages include the ability to specifically target intracellular drug molecules, conduct drug discovery for any gene with the appropriate delivery technology, and offer a more precise treatment option with potentially fewer side effects. Additionally, the company's Hetero-Duplex oligonucleotides technology facilitates the design and development of nucleic acid therapeutics, allowing for a more efficient pipeline in drug discovery.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Z-Works Inc. is a technology company based in Tokyo, Japan, specializing in Internet of Things (IoT) solutions since its founding in 2015. The company offers a range of IoT devices, including motion sensors, fire alarms, smart locks, and smart meters, along with consulting services for proof of concept and tailored sensor packages. Z-Works has developed the "Z-Works Life Engine," a cloud-based IoT platform that collects and analyzes data from Z-Wave equipped devices. This platform allows users to remotely monitor and control these devices via smartphone, addressing the needs of professionals and family members caring for the elderly. By providing data-driven insights, Z-Works aims to enhance care services in facilities, assisted living communities, and home care environments.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company focuses on the research and development of hepatocyte growth factor (HGF) and its applications in treating various medical conditions. Kringle Pharma's HGF products aim to promote regenerative healing in liver cells and other organs, addressing acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scars. Additionally, the company develops NK4, a bi-functional molecule that serves as an HGF antagonist, inhibiting tumor cell invasion and metastasis while exhibiting antiangiogenic properties. Kringle Pharma's pipeline includes recombinant human HGF for acute renal failure and skin ulcers, as well as NK4-based therapies for cancer treatment.

Starsphere is a developer of a cloud-based electronic data capture (EDC) system, primarily serving the healthcare industry. The company offers the "Everywhere Forms EDC" service, which focuses on enhancing the methods of data collection, analysis, and utilization in life sciences. By leveraging advanced technologies, Starsphere aims to improve the efficiency and safety of medical treatments, facilitating quicker access to effective therapies for patients in need. The company's vision centers on transforming the landscape of data management in healthcare, ultimately contributing to better patient outcomes.

Stem Cell & Device Laboratory, Inc. focuses on research and development, manufacturing, and sales of cellular products, devices, and integrated cell-material products specifically designed for drug discovery applications. The company specializes in creating innovative scaffold materials that enhance cell functionality and compatibility, leveraging advanced micro-engineering and nanofabrication technologies. Founded in 2014 and headquartered in Kyoto, Japan, Stem Cell & Device Laboratory is dedicated to advancing cell applications that contribute to a healthier society.

Ipoca, based in Tokyo, Japan, is a digital solution provider focused on the retail and distribution sectors. Established in 2007, the company has developed a mobile application that allows users to store and access information about various stores, enhancing their shopping experience. Its platform utilizes smartphone-based behavior data, including location information and purchase history, to help businesses attract new customers and improve customer retention. By promoting the unique attributes of local areas, Ipoca contributes to revitalizing local economies and supports the overall growth of the Japanese economy.

Nanoegg is aiming to create a medical breakthrough from skin research and to realize medical care without the use of needles.

Fileforce is a Tokyo-based company founded in 2001 that specializes in providing secure and scalable cloud file services for businesses of all sizes. The company offers a platform that allows enterprises to safely store, manage, access, and share files from various devices, including computers, tablets, and smartphones. Fileforce focuses on protecting valuable information and assets through its security management system, which includes enterprise cloud monitoring to facilitate the management of business activities such as proposals, quotations, and design documents. By enabling efficient file organization and sharing, Fileforce aims to enhance productivity and streamline operations for its clients.

TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.

Rena Therapeutics Inc. is a pharmaceutical company based in Tsukuba, Japan, founded in January 2015. The company specializes in developing nucleic acid medicines designed for innovative drug delivery systems targeting various tumors, including glioma, melanoma, and several types of leukemia and lymphoma. Rena Therapeutics focuses on addressing unmet medical needs in cancer and other difficult-to-treat diseases by leveraging the advantages of nucleic acid drugs. These advantages include the ability to specifically target intracellular drug molecules, conduct drug discovery for any gene with the appropriate delivery technology, and offer a more precise treatment option with potentially fewer side effects. Additionally, the company's Hetero-Duplex oligonucleotides technology facilitates the design and development of nucleic acid therapeutics, allowing for a more efficient pipeline in drug discovery.

Megakaryon Corporation is a medical research company based in Kyoto, Japan, with an additional office in Tokyo. Founded in 2011, it specializes in the development of blood products, particularly platelets and red blood cells, derived from human induced pluripotent stem (iPS) cell lines. The company focuses on creating transfusion medicine technologies that allow medical practitioners to maintain patients' platelet counts without relying on traditional blood donations. Megakaryon's innovative approach aims to advance the clinical application of its platelet production techniques, contributing to improved patient care in transfusion medicine.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an office in San Francisco, California. Founded in 2006, it specializes in developing immune-regulatory therapeutics aimed at treating life-threatening diseases and disorders. The company utilizes its proprietary reVax technology, which induces regulatory T cells to promote immune tolerance against specific disease-causing antigens. REGiMMUNE's product pipeline includes RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, as well as RGI-3001, a preclinical candidate for type 1 diabetes. Its portfolio also addresses a range of conditions, including allergies, autoimmune diseases, and transplantation disorders, with a focus on reducing the side effects commonly associated with conventional immunosuppressants. The company's research efforts are directed towards developing innovative solutions for various immune system disorders, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.

Ipoca, based in Tokyo, Japan, is a digital solution provider focused on the retail and distribution sectors. Established in 2007, the company has developed a mobile application that allows users to store and access information about various stores, enhancing their shopping experience. Its platform utilizes smartphone-based behavior data, including location information and purchase history, to help businesses attract new customers and improve customer retention. By promoting the unique attributes of local areas, Ipoca contributes to revitalizing local economies and supports the overall growth of the Japanese economy.

Connectec Japan Corporation specializes in the development and provision of semiconductor and electrical products. Founded in 2009 and headquartered in Myoko, Japan, the company offers foundry services for semiconductor packaging, along with technical support for surface-mount technology (SMT). Additionally, it provides evaluation, analysis, and reliability testing services. Connectec Japan is recognized for its expertise in semiconductor chip bonding and low-temperature MEMS chips, as well as small desktop semiconductor assembly equipment. The company also supports device bonding on low-heat-resistant substrates and facilitates prototype development. With a satellite office in Kyoto and sales offices in Seoul, Korea, and Suzhou, China, Connectec Japan serves a diverse clientele across various industrial applications.